Cargando…

Metabolic alkalosis: A less appreciated side-effect of imipenem cilastatin use-author's reply

Detalles Bibliográficos
Autores principales:	Panda, P. S., Dube, Surya Kumar, Sarkar, Suman, Singh, D. K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071689/ https://www.ncbi.nlm.nih.gov/pubmed/24987244 http://dx.doi.org/10.4103/0972-5229.133945

Ejemplares similares

Metabolic alkalosis: A less appreciated side effect of Imipenem-cilastatin use
por: Panda, Pragyan Swagatika, et al.
Publicado: (2013)

Metabolic alkalosis: A less appreciated side effect of Imipenem-cilastin use-comment
por: Shanbag, Preeti
Publicado: (2014)

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)

Imipenem-cilastatin-induced psychosis: a case report
por: Ninan, Jacob, et al.
Publicado: (2016)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin
por: Agudelo, Maria, et al.
Publicado: (2019)

Bacteremia caused by Elizabethkingia meningoseptica in a mechanically ventilated patient successfully treated with imipenem-cilastatin and ciprofloxacin
por: Chen, Chang-Hua, et al.
Publicado: (2017)

Reply: Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections
por: Jahangir, Abdullah, et al.
Publicado: (2021)

Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia
por: Choi, Jun Yong, et al.
Publicado: (2006)

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021)

Authors’ reply
por: Dube, Surya Kumar, et al.
Publicado: (2011)

Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
por: Kabbara, Wissam K, et al.
Publicado: (2015)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
por: Shaaban, Mona I., et al.
Publicado: (2017)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
por: Arima, Takahiro, et al.
Publicado: (2022)

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin
por: Zhu, Yanna, et al.
Publicado: (2020)

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
por: Rebold, Nicholas, et al.
Publicado: (2021)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
por: Naik, Jaesh, et al.
Publicado: (2023)

1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Kaye, Keith, et al.
Publicado: (2018)

Meropenem-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2012)

Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections: A Meta-analysis
por: Sahra, Syeda, et al.
Publicado: (2021)

Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in ICU: an open randomised multicentre study
por: Verwaest on behalf of the Belgiun Multicentre study group, C
Publicado: (1997)

Imipenem-Cilastatin versus Sulbactam-Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients
por: ÖZYILKAN, Özgür, et al.
Publicado: (1999)

Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)
por: Huo, Xiaokui, et al.
Publicado: (2019)

Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections
por: Vaziri, Ali Zaman, et al.
Publicado: (2021)

Transcatheter arterial embolization using imipenem/cilastatin sodium and microspheres for traumatic pseudoaneurysm: A case report
por: Hirano, Takaki, et al.
Publicado: (2022)

Increased antibiofilm and growth inhibitory effect of Imipenem/Cilastatin nanoliposomes against clinical Pseudomonas aeruginosa isolates
por: Milani, Faezeh, et al.
Publicado: (2023)

Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in Pseudomonas aeruginosa Isolates from Sepsis
por: de Sousa, Telma, et al.
Publicado: (2023)

A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia
por: Kollef, Marin H, et al.
Publicado: (2012)

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
por: Rizk, Matthew L., et al.
Publicado: (2018)

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia
por: Patel, Munjal, et al.
Publicado: (2021)

Authors’ reply
por: Netto, Archana B., et al.
Publicado: (2013)

1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model
por: Chen, Iris H, et al.
Publicado: (2020)

1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC)
por: Fratoni, Andrew J, et al.
Publicado: (2021)

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: a single-center retrospective study
por: Hiraki, Sakiko, et al.
Publicado: (2023)

Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia
por: Joosub, Imraan, et al.
Publicado: (2015)

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
por: Rhee, Elizabeth G., et al.
Publicado: (2018)

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
por: Sagan, Olexiy, et al.
Publicado: (2020)

Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
por: Yang, Joe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bpbuq1990cv3h1jc763uai4k5j